Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AT-527 for mild to moderate COVID-19
jRCT2031210070Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jun 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing AT-527 with Placebo (2 arms). Primary endpoint: Time to alleviation or improvement of COVID-19 symptoms. Started Jun 2021; status: completed.
02
Drugs
bemnifosbuvir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on jRCT2031210070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210070.